The short-term efficacy and safety of induction chemotherapy combined with PD-1 inhibitor or anti-EGFR in locoregionally advanced nasopharyngeal carcinoma

被引:3
作者
Xiang, Xiaoyong [1 ,2 ]
Chen, Peng [1 ,2 ]
Lan, Fengming [1 ,2 ]
Ma, Li [1 ,2 ]
Jin, Jing [1 ,2 ,3 ]
Zhang, Ye [3 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp & Shenzhen Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc, Shenzhen, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Shenzhen Hosp, Shenzhen, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc,Dept Radiat Oncol, Beijing, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
关键词
nasopharyngeal carcinoma; locoregionally advanced; induction chemotherapy; short-term efficacy; PD-1; GROWTH-FACTOR RECEPTOR; CHEMORADIOTHERAPY; MULTICENTER; RADIOTHERAPY; GEMCITABINE; EXPRESSION; PLACEBO; PHASE-3; NPC;
D O I
10.3389/fonc.2023.1110281
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeThis study aimed to investigate the short-term efficacy and safety of induction chemotherapy (IC) combined with PD-1 inhibitor or anti-EGFR in the treatment of locoregionally advanced nasopharyngeal carcinoma (LA-NPC). Methods and materialsWe retrospectively reviewed the clinical data of 206 patients with LA-NPC, including IC combined with anti-PD-1 (57 patients), IC combined with anti-EGFR (28 patients), and IC alone (121 patients). The short-term efficacy was assessed at the end of IC and one month after overall treatment. According to the RECIST v1.1, the short-term efficacy of cervical lymph nodes and primary nasopharynx foci was divided into complete remission (CR), partial remission (PR), stable disease (SD), and progressive disease (PD). The overall response (ORR) was defined as the sum of CR and PR. Acute toxicities were graded according to the CTCAE v5.0. One-way analysis of variance (ANOVA) was used to compare differences in the numerical variables among groups. Fisher Freeman-Halton test or Pearson Chi-square test was used to compare classified variables. ResultsThe ORR rates of primary nasopharynx foci in IC, anti-EGFR, and anti-PD-1 group were 68.60%, 67.9%, and 94.7%, respectively, and the corresponding rates of ORR in cervical lymph nodes were 78.5%, 71.4%, and 93.0%, respectively. There was a statistical difference in the ORR between the three groups. Further analysis showed that after IC or overall treatment, the CR rate of primary nasopharynx foci in the anti-PD-1 group was significantly higher than the other two groups. The most common adverse effects were hematotoxicity, gastrointestinal toxicity, and transaminase elevation. However, there were no statistical differences in the frequency of any common adverse effects between the three groups. ConclusionsThe addition of anti-PD-1 based on IC significantly improved the short-term efficacy of LA-NPC and toxicities were tolerable.
引用
收藏
页数:10
相关论文
共 27 条
  • [21] Current status and advances of immunotherapy in nasopharyngeal carcinoma
    Xu, Jian-Ying
    Wei, Xiao-Li
    Wang, Yi-Qin
    Wang, Feng-Hua
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [22] Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial
    Yang, Yunpeng
    Qu, Song
    Li, Jingao
    Hu, Chaosu
    Xu, Mingjun
    Li, Weidong
    Zhou, Ting
    Shen, Liangfang
    Wu, Hui
    Lang, Jinyi
    Hu, Guangyuan
    Luo, Zhanxiong
    Fu, Zhichao
    Qu, Shenhong
    Feng, Weineng
    Chen, Xiaozhong
    Lin, Shaojun
    Zhang, Weimin
    Li, Xiaojiang
    Sun, Yan
    Lin, Zhixiong
    Lin, Qin
    Lei, Feng
    Long, Jianting
    Hong, Jinsheng
    Huang, Xiaoming
    Zeng, Lingzhi
    Wang, Peiguo
    He, Xiaohui
    Zhang, Ben
    Yang, Qing
    Zhang, Xiaojing
    Zou, Jianjun
    Fang, Wenfeng
    Zhang, Li
    [J]. LANCET ONCOLOGY, 2021, 22 (08) : 1162 - 1174
  • [23] The Changing Therapeutic Role of Chemo-radiotherapy for Loco-regionally Advanced Nasopharyngeal Carcinoma from Two/Three-Dimensional Radiotherapy to Intensity-Modulated Radiotherapy: A Network Meta-Analysis
    You, Rui
    Cao, Ying-Shu
    Huang, Pei-Yu
    Chen, Lei
    Yang, Qi
    Liu, You-Ping
    Zou, Xiong
    Zhang, Yi-Nuan
    Jiang, Rou
    Zhang, Meng-Xia
    Duan, Chong-Yang
    Lin, Ai-Hua
    Hong, Ming-Huang
    Chen, Ming-Yuan
    [J]. THERANOSTICS, 2017, 7 (19): : 4825 - 4835
  • [24] The global burden of nasopharyngeal carcinoma from 2009 to 2019: an observational study based on the Global Burden of Disease Study 2019
    Yu, Hao
    Yin, Xin
    Mao, Yiran
    Chen, Meiqin
    Tang, Qiuying
    Yan, Senxiang
    [J]. EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2022, 279 (03) : 1519 - 1533
  • [25] Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III Trial
    Zhang, Yuan
    Chen, Lei
    Hu, Guo-Qing
    Zhang, Ning
    Zhu, Xiao-Dong
    Yang, Kun-Yu
    Jin, Feng
    Shi, Mei
    Chen, Yu-Pei
    Hu, Wei-Han
    Cheng, Zhi-Bin
    Wang, Si-Yang
    Tian, Ye
    Wang, Xi-Cheng
    Sun, Yan
    Li, Jin-Gao
    Li, Wen-Fei
    Li, Yu-Hong
    Mao, Yan-Ping
    Zhou, Guan-Qun
    Sun, Rui
    Liu, Xu
    Guo, Rui
    Long, Guo-Xian
    Liang, Shao-Qiang
    Li, Ling
    Huang, Jing
    Long, Jin-Hua
    Zang, Jian
    Liu, Qiao-Dan
    Zou, Li
    Su, Qiong-Fei
    Zheng, Bao-Min
    Xiao, Yun
    Guo, Ying
    Han, Fei
    Mo, Hao-Yuan
    Lv, Jia-Wei
    Du, Xiao-Jing
    Xu, Cheng
    Liu, Na
    Li, Ying-Qin
    Xie, Fang-Yun
    Sun, Ying
    Ma, Jun
    Tang, Ling-Long
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (22) : 2420 - +
  • [26] Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
    Zhang, Yuan
    Chen, Lei
    Hu, Guo-Qing
    Zhang, Ning
    Zhu, Xiao-Dong
    Yang, Kun-Yu
    Jin, Feng
    Shi, Mei
    Chen, Yu-Pei
    Hu, Wei-Han
    Cheng, Zhi-Bin
    Wang, Si-Yang
    Tian, Ye
    Wang, Xi-Cheng
    Sun, Yan
    Li, Jin-Gao
    Li, Wen-Fei
    Li, Yu-Hong
    Tang, Ling-Long
    Mao, Yan-Ping
    Zhou, Guan-Qun
    Sun, Rui
    Liu, Xu
    Guo, Rui
    Long, Guo-Xian
    Liang, Shao-Qiang
    Li, Ling
    Huang, Jing
    Long, Jin-Hua
    Zang, Jian
    Liu, Qiao-Dan
    Zou, Li
    Su, Qiong-Fei
    Zheng, Bao-Min
    Xiao, Yun
    Guo, Ying
    Han, Fei
    Mo, Hao-Yuan
    Lv, Jia-Wei
    Du, Xiao-Jing
    Xu, Cheng
    Liu, Na
    Li, Ying-Qin
    Chua, Melvin L. K.
    Xie, Fang-Yun
    Sun, Ying
    Ma, Jun
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (12) : 1124 - 1135
  • [27] Mismatch repair status and high expression of PD-L1 in nasopharyngeal carcinoma
    Zhao, Liang
    Liao, Xiyi
    Hong, Ganji
    Zhuang, Yanzhen
    Fu, Kaili
    Chen, Peiqiong
    Wang, Yuhuan
    Chen, Haojun
    Lin, Qin
    [J]. CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 1631 - 1640